RNXT
RenovoRx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.39
+0.84%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.0M | 1.1M | 43.0K | — | — |
| Cost of Revenue | 308.0K | 327.0K | — | — | — |
| Gross Profit | 1.7M | 796.0K | 43.0K | — | — |
| Operating Expenses | |||||
| R&D Expense | 5.6M | 6.3M | 6.0M | 5.7M | 4.3M |
| SG&A Expense | 9.6M | 7.0M | 5.0M | 5.7M | 5.6M |
| General & Admin Expense | 4.6M | 7.0M | 5.0M | 5.7M | 5.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (143.0K) | — | — | — | — |
| Total Operating Expenses | 15.1M | 13.3M | 11.0M | 11.4M | 9.9M |
| Cost and Expenses | 15.4M | 13.6M | 11.0M | 11.4M | 9.9M |
| Operating Income (EBIT) | (13.4M) | (12.5M) | (11.0M) | (11.4M) | (9.9M) |
| Non-Operating | |||||
| Interest Income | 233.0K | 427.0K | 384.0K | — | 57.0K |
| Interest Expense | — | — | — | 108.0K | 57.0K |
| Net Interest Income | 233.0K | 427.0K | 384.0K | (108.0K) | — |
| Other Non-Op Income/Expense | 1.1M | 1.3M | 2.2M | 1.2M | 61.0K |
| Non-Operating Income (excl Interest) | (1.1M) | (1.3M) | (2.2M) | (1.3M) | (118.0K) |
| EBT (Pre-Tax Income) | (12.3M) | (11.2M) | (8.8M) | (10.2M) | (9.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (12.3M) | (11.2M) | (8.8M) | (10.2M) | (9.9M) |
| Earnings from Cont. Ops | (12.3M) | (11.2M) | (8.8M) | (10.2M) | (9.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (12.3M) | (11.2M) | (8.8M) | (10.2M) | (9.9M) |
| Per Share | |||||
| Basic EPS | ($0.32) | ($0.32) | ($0.37) | ($0.50) | ($0.54) |
| Diluted EPS | ($0.32) | ($0.32) | ($0.37) | ($0.50) | ($0.54) |
| Revenue Per Share | $0.04 | $0.03 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 47.3M | 35.3M | 23.6M | 20.6M | 18.1M |
| Diluted Shares Outstanding | 47.3M | 35.3M | 23.6M | 20.6M | 18.1M |
| Profitability Metrics | |||||
| EBITDA | (12.3M) | (11.2M) | (8.8M) | (10.1M) | (9.8M) |
| D&A | 1.0K | 2.0K | — | 6.0K | 6.0K |
| EBIT | (12.3M) | (11.2M) | (8.8M) | (10.1M) | (9.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026